Overexpressed on the surface of prostate cancer cells, PSMA provides an ideal binding site for both selective radiotherapy and high-sensitivity molecular imaging, warranting a closely interrelated diagnostic and therapeutic process [2]. This evidence concerns the gene FOLH1 and prostate carcinoma.